GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week, customers ...

GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy ...

GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with ...

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

Novo Nordisk reduces Ozempic's price to $499/month for self-paying patients, enhancing access to essential diabetes treatment ...

Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for ...

GoodRx offers coupons for reduced prescription drug prices at retail pharmacies. The company says patients will be able to ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

People who are prescribed Ozempic to treat type 2 diabetes, but whose insurance does not cover it, or who don’t have ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both of Novo Nordisk's GLP-1 drugs, Ozempic ...

(Reuters) -Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying ...